This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Cara Therapeutics stock | $13.93

Own Cara Therapeutics stock in just a few minutes.

Posted

Fact checked

Cara Therapeutics, Inc is a biotechnology business based in the US. Cara Therapeutics shares (CARA) are listed on the NASDAQ and all prices are listed in US Dollars. Cara Therapeutics employs 76 staff and has a trailing 12-month revenue of around USD$27.5 million.

How to buy shares in Cara Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Cara Therapeutics. Find the stock by name or ticker symbol: CARA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cara Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$13.93, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Cara Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Cara Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cara Therapeutics share price

Use our graph to track the performance of CARA stocks over time.

Cara Therapeutics shares at a glance

Information last updated 2020-12-02.
Latest market close USD$13.93
52-week range USD$8.88 - USD$18.32
50-day moving average USD$14.4234
200-day moving average USD$15.5581
Wall St. target price USD$32.63
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.166

Buy Cara Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cara Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cara Therapeutics price performance over time

Historical closes compared with the close of $13.93 from 2020-10-19

1 week (2020-11-27) -6.82%
1 month (2020-11-05) 0.29%
3 months (2020-09-04) -8.60%
6 months (2020-06-05) -9.37%
1 year (2019-12-05) -13.64%
2 years (2018-12-04) -21.57%
3 years (2017-12-05) 11.62%
5 years (2015-12-04) -2.66%

Cara Therapeutics financials

Revenue TTM USD$27.5 million
Gross profit TTM USD$-93,934,000
Return on assets TTM -31.29%
Return on equity TTM -58.34%
Profit margin 0%
Book value $2.726
Market capitalisation USD$732 million

TTM: trailing 12 months

Shorting Cara Therapeutics shares

There are currently 3.8 million Cara Therapeutics shares held short by investors – that's known as Cara Therapeutics's "short interest". This figure is 0.1% up from 3.8 million last month.

There are a few different ways that this level of interest in shorting Cara Therapeutics shares can be evaluated.

Cara Therapeutics's "short interest ratio" (SIR)

Cara Therapeutics's "short interest ratio" (SIR) is the quantity of Cara Therapeutics shares currently shorted divided by the average quantity of Cara Therapeutics shares traded daily (recently around 443268.75). Cara Therapeutics's SIR currently stands at 8.64. In other words for every 100,000 Cara Therapeutics shares traded daily on the market, roughly 8640 shares are currently held short.

However Cara Therapeutics's short interest can also be evaluated against the total number of Cara Therapeutics shares, or, against the total number of tradable Cara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cara Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Cara Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.0871% of the tradable shares (for every 100,000 tradable Cara Therapeutics shares, roughly 87 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cara Therapeutics.

Find out more about how you can short Cara Therapeutics stock.

Cara Therapeutics share dividends

We're not expecting Cara Therapeutics to pay a dividend over the next 12 months.

Have Cara Therapeutics's shares ever split?

Cara Therapeutics's shares were split on a 1:2 basis on 16 January 2014. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cara Therapeutics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Cara Therapeutics shares which in turn could have impacted Cara Therapeutics's share price.

Cara Therapeutics share price volatility

Over the last 12 months, Cara Therapeutics's shares have ranged in value from as little as $8.88 up to $18.32. A popular way to gauge a stock's volatility is its "beta".

CARA.US volatility(beta: 1.77)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cara Therapeutics's is 1.7717. This would suggest that Cara Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cara Therapeutics overview

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site